Woburn, MA Rgenta Therapeutics has graduated from LabCentral, a shared laboratory in Cambridge, to a dedicated facility at TradeCenter 128. The biotech startup leased 5,400 s/f at the prominent business and technology campus, which is managed by Cummings Properties.

Rgenta is developing oral treatments for historically incurable diseases. Its team of small-molecule drug developers is currently focused on pioneering new medicines for cancers and neurological disorders. In April of 2020, the venture capital-backed firm announced its receipt of $20 million in seed funding from multiple investors.

“Because our science has such wide applicability, our operation is rapidly expanding,” said Rgenta CEO and co-founder Simon Xi, Ph.D. “Having outgrown our shared space in Cambridge, we were determined to find a convenient, high-value location that would support our continued evolution.”

According to Xi, Rgenta hopes to grow its staff in its new location, ramping up the operations at the new lab over the next several months.

Cummings Properties account manager Eric Lawless worked with Newmark director Catie Tilton on the lease, which included a custom lab and office buildout.

“With the current scarcity of available lab space in greater Boston, biotech firms are finding it advantageous to lease from a property manager with in-house design and construction teams,” said Lawless. “Cummings’ ability to efficiently deliver a high-quality, cost-effective lab facility within an established life science hub was a big draw for Rgenta.”

Rgenta’s space is a Biosafety Level 2 facility and features a newly constructed cell-culture room, specialty gas distribution, and an expansive window line as well as new benchwork, fume hoods, and HVAC. Floor-to-ceiling glass partitions separate its offices from its laboratory, allowing staff to enjoy a sweeping view that includes the Boston skyline from virtually any vantage point in the suite. Cummings’ architecture and construction teams designed and built the facility in four months.